1. Vaccine Research &
Innovation 2010
Exploring global opportunities in vaccine research and development
2nd – 3rd September 2010,BSG House, London, UK BOOK NOW!
Key Speakers
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Alex Kudrin, Medical Assessor, Biological PLAT, MHRA
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Dr Jon Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck
Dr Carmen Giefing, Group Leader, Antigen Identification - Molecular Microbiology, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Silver Sponsor
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised by
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/vaccinno

2. Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague, Silver Sponsor:
Increasing use of novel technologies has boosted the vaccines industry worldwide. Encorium is a full service CRO with experience in more than 30
Recent technological breakthroughs in vaccine research, manufacturing and countries worldwide. With expertise and investigator networks we have
delivery, promise a bright future for the new generation of vaccines, particularly for serviced successfully over 20 clients and recruited over 55,000 subjects/
chronic conditions such as cancer, auto-immune diseases and nicotine addiction. patients in pediatric, adult and elderly populations for prophylactic and
According to Visiongain’s recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccine. By establishing a global CRO network Encorium
is strengthening its offerings in vaccine development. Encorium ensures efficiency in
therapeutic vaccines will significantly expand the vaccines market contributing to
clinical trial design and execution. Having been trusted the conduct of some of the
rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, largest vaccine studies performed we understand that our success is rooted in our
led by cervical cancer vaccines, is presently one of the most lucrative areas for clients success and we are committed to becoming a world leading vaccine CRO.
vaccine manufacturers. Advances are also being made in almost all adjunct areas
of vaccine research, such as the mode of delivery, use of combination vaccines, For further information please visit www.encorium.com
vaccine adjuvant, and vaccine manufacturing. Media Partners:
Our Vaccine Research & Innovation conference is designed to implement
PharmiWeb.com is the leading industry-sponsored portal for
successful strategies and innovative technologies to develop more effective the pharmaceutical sector. Supported by most of the leading
vaccines. Gain insights through industry led case studies and discussions with pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news,
key decision markers from the vaccines sector. Network and collaborate with features, events listings and international jobs to industry professionals across Europe
global professionals to keep up-to-date with future trends and exploring business and the US.
opportunities at the two-day event. For further information please email: corporate@pharmiweb.com
By attending this conference you will gain insights on: BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
• Overcoming challenges to cancer vaccine development WORLD. It is based and located in Warsaw, Poland. Biotechnology
World was founded in 2007 to provide the world’s biotech
• Evaluating the immune response to combination vaccines and pharma information and market to make it universally accessible and useful
• Accelerating new vaccine introduction in the developing world for scientific and business processes. Its first step to fulfilling that mission was
building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene
information in different channels. BIOTECHNOLOGY EUROPE offers companies
therapy, protein based drugs completed internet public relations, publication and marketing solutions. One of the
mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma
• ssessing the key immunological observations on clinical development of
A Sector in Europe to global biotechnology, pharmaceutical and life science activities.
pandemic infl uenza A (H1N1) vaccines
For further information please visit www.biotechnology-europe.com
• Examining the safety challenges on new vaccine introduction
Future Pharmaceuticals has forged powerful relationships with
Driving the Industry Forward | www.futurepharmaus.com
• mplementing strategies for manufacturing and purification of conjugate
I key industry leaders to provide a platform for successful brand
vaccines recognition, and for senior decision-makers to have the means to
procure and plan implementation strategies based on the topics covered. Positioned to
• Good supply chain management practices for vaccine distribution be an authoritative resource within top pharma companies as well as small, specialty,
I look forward to meeting you at the conference and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration
into a highly targeted and responsive audience, bridging the gap between the
Best regards industries’ top issues and the solutions top-tier vendors can provide.
For further information please visit: www.futurepharmaus.com
InPharm is the online platform for exclusive pharmaceutical news,
Maninder Paul comment, contracts, services, jobs and events and is home to
Conference Producer InPharmjobs.com, Pharmafile and Pharmafocus.
For further information please visit: www.In-Pharm.com
‘Pharma Connections Worldwide® is the leading professional business
networking website focused in the Pharmaceutical, Biotechnology
Who will be there? and Life Sciences research industry. Our goal is to provide a conduit
for delivery of premiere content coupled with the right clientele in order to facilitate business
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area development opportunities among industry professionals responsible for making key decisions
Heads, in: in a global marketplace. ‘
For further information please visit: www.pharmaconnections.com
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D Sponsorship and exhibition opportunities:
• In-licensing and out-licensing
• Pharmacovigilance and safety testing This event offers a unique opportunity to meet and do business with some
• Regulatory affairs of the key players in the pharmaceutical and biotech industries. If you have a
• Strategic product development service or product to promote, you can do so at this event by:
• External research
• Hosting a networking drinks reception
• Manufacturing/production
• Chemistry manufacturing and controls (CMC) • Taking an exhibition space at the conference
• Procurement & purchasing
• Cold chain supply and lyophilisation • Advertising in the delegate documentation pack
• Strategic alliances
• Providing branded bags, pens, gifts, etc.
• Clinical product resourcing
• Supply outsourcing project management If you would like more information on the range of sponsorship or exhibition
• Contract management possibilities for visiongain's Vaccine Research & Innovation Conference, please
• Process development contact us:
• Business development
• Drug discovery & delivery Ronald Magali, +44 (0)20 7549 9934
• Patent law Ronald.magali@visiongainglobal.com
• Investment and venture capital

3. Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments 12:50 Networking lunch
13.50 Leveraging a CRO in accelerating
10:00 Opening address from the chair
vaccine development
• Agility in a regulated environment
10:10 Regulatory challenges in the approval process • Experiences
for novel vaccine adjuvants • Efficiencies
• Regulation and evaluation process of new adjuvants in vaccines
epresentative
R
• ifferences in the global regulatory requirements and overcoming
D Encorium
these challenges
• ngaging with regulators and contributing to the evolution of
E
regulatory framework 14:10 Development of a 15-valent pneumococcal -
conjugate vaccine
• ntegrating your global regulatory strategy and product
I
development plan • lobal epidemiological trends following pneumococcal-conjugate
G
vaccine introduction
r David Kirke
D
Associate Director - Regulatory Affairs • evelopment of a polysaccharide-conjugate vaccine with expanded
D
serotype coverage
ERA Consulting
• valuation of vaccine immunogenicity in rabbit and infant-monkey
E
model systems
10:50 Evaluating the immune response to r Jon Heinrichs
D
combination vaccines Senior Research Fellow, Vaccine Basic Research
Merck
• igh sensitivity T cell immune monitoring of novel vaccines,
H
gene therapy, protein based drugs
• mmune monitoring during pre clinical and clinical trials
I 14:50 Afternoon refreshments
to detect adverse immune reactions to gene therapy and
protein based drugs early
r Thomas O Kleen
D
15:10 Regulatory and clinical development challenges with
Director, Business and Technology Development cancer vaccines
Cellular Technology • Current status of new therapeutic vaccines development;
• Clinical lessons and learning’s from recent product development;
• egulatory principles and guidelines on clinical development of new
R
11:30 Morning refreshments therapeutic vaccines
r Alex Kudrin
D
11:50 CMC and pre-clinical development of a cellular Medical Assessor, Biological PLAT
tumour vaccine product MHRA
• urrent-generation high-throughput sequencing
C
• Establishing new assays for high-throughput screening 15:50 Challenges to cancer vaccine development
• ptimised system for rapid generation of localisation and affinity
O
• verview of the main immune responses
O
purification-tagged mammalian stable cell lines • Identifying targets for immune therapy
• Stabilisation of cell lines • New vaccine development and current clinical trials
r Klaus Kühlcke
D r Barbara Guinn
D
Eufets Cancer Sciences Division
University of Southampton
12.10 Development of avian cell lines dedicated to
vaccines manufacturing 16:30 Closing remarks from the chair
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins 16:40 Networking drinks
ean Marc Balloul
J Take your discussions further and build new
New Venture Development Director relationships in a relaxed and informal setting.
Transgene
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2010

4. Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments 13:10 Networking lunch
10:00 Opening address from the chair
14:10 Case study: Developing the next generation of
therapeutic vaccines
10:10 Development of a pneumococcal vaccine comprising
CASE STUDY
T
he case study will feature novel, therapeutic vaccines for the treatment
highly conserved proteins of cancer and key intracellular pathogens via specific manipulation and
• Discovery of a novel class of highly conserved vaccine antigens augmentation of the patient cellular immune responses.
• pproach for new-generation vaccines is the use of nonpolysaccharide
A ior Carmon
L
antigens that are conserved among pneumococcal strains Founder & CEO
• hanging epidemiology of pneumococcal infection
C Vaxil Biotherapeutics
• Immunological considerations and correlates
r Carmen Giefing
D
Group Leader, Antigen Identification - Molecular Microbiology 14:50 Surface proteome analysis as a fast-track to
Intercell vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
10:50 From trial and error to rational design of
adjuvant vaccines • Identification and validation of new targets for group A Streptococcus
• Adjuvant need not induce side effects: A different concept uido Grandi
G
Senior Project Leader
• ISCOM, adjuvant for newborns and elderly
Novartis Vaccines and Diagnostics
• Antigen sparing an essential aspect
• Broadening of immune response
ror Morein
B 15:30 Afternoon refreshments
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
15.50 Vaccine Development of HIV-1 vaccines inducing
protective T cell responses
11:30 Morning refreshments
• Design and pre-clinical evaluation
• Towards an HIV T cell-based vaccine
• Strategies eliciting HIV-1-specific T cell responses
11:50 Case Study: Key immunological observations on • Natural proteins as vaccine antigens
clinical development of pandemic influenza A
r Tomas Hanke
D
(H1N1) vaccines Reader in Immunology, Group Head/PI Supervisor,
CASE STUDY
r Bassam Hallis
D HIV-1 Vaccine Development
General Project Manager Weatherall Institute of Molecular Medicine
Centre for Emergency Preparedness and Response
Health Protection Agency
16.30 Accelerating new vaccine introduction in
the developing world
• eeting the challenges in introducing new vaccines: Logistics,
M
12:30 Vaccine development & early clinical
supply and quality control issues
research (Phase I)
• Overcoming shortage and delays
• Phase I study design
• Good supply chain management practices for vaccine distribution
• Managing sponsors
• Managing the vaccines
• Operational execution 17:10 Chair’s closing remarks
ndrew Nolan
A
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines 17:20 End of Conference
Quintiles

5. Registration Form
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Angel
For multiple bookings Pentonville Road
Photocopy this form Conf. code VG Vaccine Research &
Ci
t
ty
Ro
Innovation 2010
ad
Standard Prices
2nd - 3rd September 2010 Old Street
Conference only Fee: £1299 VAT: £227.33 Total: £1526.33 Old Street
Location: SG Conference Centre
B
Address:
226-236 City Road
City Road
Promotional Literature Distribution London
Distribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £174.83 Total: £1173.83
Details How to book
Forename: Surname: Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/vaccinno
Job Title: Company: UK Office:
Tel: +44(0) 20 7336 6100
Main Switchboard Number: Fax: +44(0) 20 7549 9932
Visiongain Ltd
BSG House
Address:
226-236 City Road
London
EC1V 2QY
UK
Country: Postcode: General information
Venue: Directions: BSG Conference Centre 226 – 236 City Road, London, EC1V 2TT. United
Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London
City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503,
http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Email:
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
Signature: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
right to charge interest on unpaid invoices.
I confirm that I have read and agree to the terms and conditions of booking
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
Methods of payment after one month before the start of the event. Should you decide to cancel after this date, the full invoice
must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
Payment must be made in sterling between conferences. However, if you cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email, fax or post. Name changes and
By Mail: Complete and return your signed registration form together with your cheque payable substitutions must be from the same company or organisation and are not transferable between
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK countries. Please note that discounted delegates places at a visiongain event are non refundable.
By Fax: Complete and fax your signed registration form with your credit card details Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
excluding substitutions/name changes, requested by the customer. This will be charged to the
to +44 (0) 20 7549 9932 customer by credit card prior to the changes being made.
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
By Bank Transfer: expenses, which may be incurred by the customer as a consequence of the event being postponed or
cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
Visiongain Ltd A/C: visiongain Ltd
cost of the registration, travel and expenses.
Barclays Bank Sort Code: 20-71-64 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Piccadilly Branch Account No: 6038 7118 Protection Act 1988. Your personal information contained in this form may be used to update you on
48 Regent Street Swift Code: BARC GB22 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
London, W1B 5RA IBAN: GB80 BARC 20716460387118 wish for your details to be amended, suppressed or not passed on to any external third party, please
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Please debit my credit card: EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Access MasterCard Visa American Express Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
Card number: This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
Expiry Date: incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Security number (last 3 digits on back of credit card): How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Signature:
Unable to attend
Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
with your payment. You will be emailed over the speaker presentations two weeks after the event.
Yes please email me the speaker presentations for Price:£550 VAT:£96.25 Total:£646.25
News updates
Office use only
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/vaccinno